Carbapenem-hydrolyzing beta-lactamase KPC · SINGLE PROTEIN · Klebsiella pneumoniae
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Carbapenem-hydrolyzing beta-lactamase KPC shows approved-linked disease relevance led by urinary tract infection. 2 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q9F663. Start with urinary tract infection, then reuse UniProt Q9F663 as the stable protein anchor across project notes and exports.
Start with urinary tract infection, then reuse UniProt Q9F663 as the stable protein anchor across project notes and exports.
Carbapenem-hydrolyzing beta-lactamase KPC shows approved-linked disease relevance led by urinary tract infection. 2 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with urinary tract infection because it currently carries approved-linked support. Linked drugs include VABORBACTAM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyCarbapenem-hydrolyzing beta-lactamase KPC-2
Review this target as Carbapenem-hydrolyzing beta-lactamase KPC, mapped to UniProt Q9F663. ChEMBL maps the protein component as Carbapenem-hydrolyzing beta-lactamase KPC-2. Sequence length is 293 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Carbapenem-hydrolyzing beta-lactamase KPC as ChEMBL target CHEMBL6132, mapped to UniProt Q9F663. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Carbapenem-hydrolyzing beta-lactamase KPC is the right protein anchor across sources, using UniProt Q9F663 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why urinary tract infection is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Carbapenem-hydrolyzing beta-lactamase KPC |
| Target Type | SINGLE PROTEIN |
| Organism | Klebsiella pneumoniae |
| UniProt | Q9F663 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Carbapenem-hydrolyzing beta-lactamase KPC-2 |
| UniProt Accession | Q9F663 |
| Component Type | Protein |
| Sequence Length | 293 aa |
Carbapenem-hydrolyzing beta-lactamase KPC-2
Review this target as Carbapenem-hydrolyzing beta-lactamase KPC, mapped to UniProt Q9F663. ChEMBL maps the protein component as Carbapenem-hydrolyzing beta-lactamase KPC-2. Sequence length is 293 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Carbapenem-hydrolyzing beta-lactamase KPC shows approved-linked disease relevance led by urinary tract infection. 2 more disease programs remain visible in the same review block.
Start review with urinary tract infection because it currently carries approved-linked support. Linked drugs include VABORBACTAM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL5483057 | 7.36 | IC50 | 44.0 | Preclinical |
| CHEMBL1689063 | 6.73 | IC50 | 186.0 | Approved |
| CHEMBL404 | 6.43 | IC50 | 370.0 | Approved |
| CHEMBL3989959 | 6.06 | IC50 | 869.0 | Clinical |
| CHEMBL777 | 4.98 | IC50 | 10500.0 | Approved |
| CHEMBL777 | 4.96 | Ki | 11000.0 | Approved |
| CHEMBL404 | 4.13 | Ki | 74000.0 | Approved |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 25 | 6 | 5.8 |
| assay format | 3 | 1 | 6.4 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 1 | 0 | — |